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Vaporisers are a salient component of modern 
anaesthesia workstation and are integrated with the 
anaesthesia workstation to match the accuracy and 
safety standards. Since the evolution of the anaesthesia 
machine into a workstation, the vaporisers have 
evolved too; integrating electronics with pneumatics. 
These electronic vaporisers have been made very 
safe for use and have incorporated different priority 
alarms to warn the end-user whenever there is a 
malfunction. In addition, with the use of more potent 
volatile agents and agents with low boiling points, 
the modern vaporisers have the ability to control the 
vapour output with extreme accuracy even when the 
anaesthesia machine fresh gas flows (FGF) are changed 
to alter the anaesthetic depth rapidly. The high-end 
anaesthesia workstations have an option to set the 
target end-tidal anaesthetic concentration (ETAC) 
and these vaporisers are designed to respond to such 
demands with precision. Hence, this review aims to 
describe the components, electronics and pneumatic 
integration, operation and safety features incorporated 
in modern vaporisers to yield to end-user demands.
A thorough literature search was done from 
inception till March 2019 using databases/search 
engines (Medline, Embase, Scopus, PubMed and 
Google Scholar). The articles were manually searched 
by the authors for cross-referencing. All the articles 
published in English were searched. We used 
the following keywords ‘anaesthesia machine’, 
‘anaesthesia workstation’, ‘gas delivery’, ‘vaporisers’, 
‘Aladin cassette’, ‘injection vaporiser’ and ‘AnaConDa’. 
Amongst 2400 articles (review articles, primary 
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ABSTRACT
The output of inhalational agents from modern vaporisers are both electronically and pneumatically 
controlled. They are designed to deliver set agent concentrations accurately with low fresh gas 
flows and possess enhanced safety features. The purpose of this review article is to give an 
overview of three modern vaporisers, namely, the Aladin cassette vaporiser, injection vaporisers 
and AnaConDa™. The Aladin cassette is integrated with Datex Ohmeda S/5 ADU and GE Aisys 
anaesthesia machines. The electronic vapour control unit is incorporated within the anaesthesia 
machine. The agent specific cassettes act as a detachable vaporising chamber. The system can 
work as a variable bypass and measured flow vaporiser but requires a power supply to function. 
Injection vaporisers can achieve the set end‑tidal agent concentration very rapidly with even 
metabolic flow rates. Hence, anaesthetic depth can be rapidly altered with minimal wastage and 
theatre pollution. The two types of injection vaporisers, namely, Maquet and DIVA™ are customised 
to function with Maquet FLOW‑i and the Drager Zeus anaesthesia machine, respectively. 
AnaConDa™ is a combination of vaporiser and humidity and moisture exchange filter which can 
be fitted in the ventilatory circuit. It is primarily designed for use in intensive care for sedation and 
out of operating room use.
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manuscripts, case reports, letter to the editors and 
chapters from books) the relevant information 
pertinent to the topic were sorted out. The information 
available is very limited and only 14 references could 
be included.
ALADIN CASSETTE VAPORISER
Aladin cassette vaporiser electronically controls 
the gas flow and vapour concentration. This system 
is used in the Datex Ohmeda S/5 ADU and GE 
Aisys anaesthesia workstation.[1] The vaporiser 
system consists of an electronic vapour control unit 
internalised within the anaesthesia workstation and 
coded agent cassettes that contain the anaesthetic 
liquid that serves as a detachable vaporising chamber. 
The cassettes are coloured and magnetically coded 
and are designed to deliver five different inhalational 
anaesthetics (halothane, isoflurane, enflurane, 
sevoflurane and desflurane).
The structural and functional components: The 
Aladin cassette comprises of two parts, namely, 
the agent-specific vaporiser chamber (cassette) and 
the central processing unit (CPU) which is integrated 
into the anaesthesia machine. The cassette is a 
leakproof metal box which has a smaller front portion 
which is colour-coded to the specific agent and a larger 
rear portion that is black in colour. The front portion 
has an agent-specific filling system, a glass window 
to display the level of the anaesthetic liquid and a 
handle with a lever for locking the cassette in the slot 
provided on the anaesthesia machine. This portion 
also houses the contact for the electronic temperature 
sensor and liquid anaesthetic agent level. There are 
four copper coloured circles that can be seen on the 
top surface of the front of the cassettes. These are the 
copper contacts of the electronic bus that power the 
capacitor plates which sense the level of the liquid 
agent. Information from the liquid level sensor and 
vaporiser temperature data is transmitted by this 
electronic bus to the anaesthesia workstation. There 
are also five agent identification magnets arranged in a 
sequence in the front portion of the cassette, but these 
are not visible externally. These signature magnets 
allow the anaesthesia machine to identify the agent 
cassette that is inserted into the machine slot.
There are three types of Aladin 2 cassettes (which are 
currently used in modern anaesthesia workstations) 
filler systems. Enflurane and isoflurane use a 
colour-coded, Easy-Fil mechanism. Sevoflurane 
cassettes are available with a colour-coded, Easy-Fil or 
Quik-Fil mechanism. On the other hand, desflurane 
cassettes have a filling mechanism that is compatible 
with Saf-T-Fil desflurane bottles [Figure 1a]. These 
cassettes can hold up to 250 mL of liquid anaesthetic.
The larger rear section of the cassette is the vaporising 
chamber containing the liquid anaesthetic at its 
SVC (saturated vapour concentration). The cassette is a 
specially designed liquid sump that requires main power 
supply or battery backup and adequate oxygen and air 
pressure to work. It is filled with a synthetic material 
soaked in liquid anaesthetic that is arranged as lamellae 
with metal plates interspersed between the lamellae. 
They are so arranged to form a convoluted pathway for 
the FGF so that the surface area available for vaporisation 
is maximised. The back panel has an inflow valve and 
outflow valve which are spring-loaded mechanical ball 
valves to prevent agent leak during transport [Figure 1b].
Functional Anatomy: The Aladin cassette vaporiser is 
concentration calibrated, flow over and electronically 
thermo-compensated that works both as variable 
bypass and measured flow vaporiser.[2,3]
Function as a variable bypass: Aladin cassette vaporiser 
is in many ways similar to the other variable bypass 
vaporisers such as Tec 4, Tec 5 and Tec 7 vaporisers, 
however, there are several important differences. The 
vaporiser consists of (a) a bypass chamber which 
houses a backpressure regulator that builds pressure 
at the input to the vaporiser if necessary, to drive gas 
through the cassette, and this is permanently housed 
in the anaesthesia machine and (b) a detachable 
cassette that serves as the vaporising chamber. The 
two separate parts must come together to form a 
functioning vaporiser. The liquid anaesthetic is 
filled in the front section and enters the rear section 
through a one-way valve. The FGF and the vaporiser 
output are electronically controlled with the necessary 
hardware and software built into the anaesthesia 
machine [Figure 2].
Figure 1: Desflurane Aladin Cassette Vaporiser. (a) Front panel 
showing the Saf‑T‑filling mechanism compatible with Desflurane 
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Gas flow: The FGF is first split into two portions; the 
bulk of the FGF passes through the bypass chamber 
and a smaller portion passes through a mechanical 
one-way valve and an electronic inflow close valve. 
It then enters the cassette by passing through the 
open mechanical ball valve in the rear panel of the 
cassette. This cassette inflow valve only opens when 
the cassette is plugged into the slot in the anaesthesia 
machine. The FGF enters the vaporising chamber to 
pick up vapour at its saturated vapour pressure (SVP). 
The gas saturated with anaesthetic vapour exits the 
cassette/vaporising chamber through the cassette 
outflow valve and passes sequentially through an 
electronic outflow close valve, a liquid flow prevention 
valve and a proportional flow valve. Finally, it passes 
through the agent flow measurement device and into 
the outlet of the control unit, gets mixed with the 
bypass chamber gas and is delivered at the common 
gas outlet [Figure 2].
Function as a measured flow vaporiser: To deliver 
the requested concentration of the volatile agent, the 
outflow from the cassette (the variable control of flow 
through the cassette) is controlled by a proportional 
valve. Hence, the control loop of the system 
depends upon the cassette flow and not the agent 
concentration (that amount of cassette flow is added 
to the bypass chamber flow to meet the desired set 
concentration of the volatile agent) which is delivered 
to the common gas outlet [Figure 3a].
Delivery of the set agent concentration: Volatile 
anaesthetic agent is delivered from the cassette-based 
on the mixer output pressure and the cassette pressure. 
When the cassette pressure exceeds the mixer output 
pressure the entire FGF is directed through the bypass 
chamber and inflow valve closes to prevent any gas 
flow to the cassette [Figure 3b]. The excess pressure 
in the cassette is then brought down by metering 
out some of the gas containing inhalational agent 
from the cassette pressure relief valve attached to the 
scavenging system. Once the cassette pressure falls 
below the mixer output pressure some of the FGF is 
again routed through the cassette [Figure 3c]. Hence, 
the control loop will differ depending upon whether 
the entire FGF is routed through the bypass chamber 
or to split between cassette and bypass chamber. 
When the entire FGF is through the bypass chamber, 
the control loop depends on mixer flow. On the other 
hand, when FGF is split between the cassette and the 
bypass chamber, the control loop for delivery of the 
volatile agent depends on the reported mixer flow, 
cassette flow, cassette pressure and temperature.
The flowmeters: The inflow and outflow flowmeters 
determine the flow by detecting the pressure 
drop across a fixed flow restrictor (pressure drop 
is proportional to gas flow over fixed resistance). 
A zeroing valve is incorporated into each of the 
flowmeters that temporarily will short the pressure 
transducer’s ports together for an accurate zero 
measurement. These zeroing valves also prevent agent 
condensation as they are energised during standby to 
heat the flowmeter manifold.
Temperature control and compensation: Vapour 
concentration of the volatile agent is determined by 
SVP divided by the total cassette pressure (SVP/Total 
cassette pressure).[2] Hence, if the temperature falls 
the SVP of the volatile agent will fall and therefore 
the proportional valve will accordingly govern the gas 
flow output from the cassette. Finally, temperature 
compensation is achieved by the central processing 
unit. The microprocessor receives input from multiple 
Figure 2: Schematic illustration explaining the components and basic functional aspect of Aladin 2 cassette vaporiser. FGF = Fresh gas flow
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sources every 200 ms including FGF rate, carrier gas 
composition, set vapour concentration, liquid level 
and temperature in the vaporising chamber (sump) 
and controls vapour output electronically. To maintain 
cassette temperature, there is a fan mounted beneath 
the Aladin cassette housing operating at cassette 
temperatures below 17°C. This serves to heat the 
cassette when large amounts of volatile anaesthetic are 
being vaporised and heat is lost.
The difference in the delivery of desflurane vapour 
compared to other agents: The desflurane Aladin cassette 
works differently compared to that of other agents. When 
the temperature of desflurane inside the cassette is less 
than 22.8 , it functions as a flow over variable bypass 
vaporiser just as it is for the other agents. However, 
when the cassette temperature is above 22.8°C, which is 
the boiling point of desflurane, the inflow valve closes 
and no fresh gas enters the cassette. The vaporiser now 
behaves as an injector and calculated amount of vapour 
is injected out of the proportional valve to mix with the 
fresh gas from the bypass.
Aladin 1 and Aladin 2 cassettes: There are some 
differences between the originally introduced Aladin 
1 cassettes [Figure 4] and the currently used Aladin 2 
cassettes [Figure 2]. The liquid level display window 
is bigger in Aladin 2 and the handle has a locking 
lever. There is also an additional liquid level sensor 
which gives input back to the anaesthesia workstation 
via an electronic bus, which also conveys vaporiser 
temperature data. Aladin DES and all Aladin 2 
cassettes have electronic agent level sensing. Aladin 
1 and Aladin 2 both measure temperature. While 
Aladin 1 had very simple temperature measurement 
Aladin 2 cassettes are more advanced having internal 
temperature sensing mechanism. A symbol indicating 
enhanced temperature sensing is seen on the front of 
the cassette [Figure 2].
Salient features of Aladin Cassette
The vapour output is not influenced by atmospheric 
pressure changes since the vapour concentration is 
determined by the separate environment that is the 
total cassette pressure. The electronic control in the 
cassette allows for automatic record keeping and 
usage calculation. Agent control is monitored by the 
microprocessor up to 200 ms during operation. Aladin 
cassette vaporiser is electronically controlled hence, it 
cannot function in the presence of power failure when 
the workstation battery gets depleted.
Aladin cassette is featured with specific safety features 
to ensure safe and constant delivery of vapours to the 
Figure 3: Interplay of the cassette of cassette pressure and mixer output pressure in Aladin cassette function. (a) Cassette pressure and mixer 
output pressure regulating agent delivery from cassette, (b) Cassette pressure exceeds mixer output pressure and the gas flow to the cassette 
is stopped (c) Cassette pressure is lowered down as agent is metered out to the scavenging system and cassette pressure falls below mixer 
output pressure and the gas is routed through the cassette. FGF = Fresh gas flow, F = Flowmeter, P = Pressure sensor, Cassette pr. relief 
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patients. The cassette features with accurate overfill 
protection and the level sensing are electronic and 
more accurate than only visual sensing. There is 
a liquid spill prevention valve that prevents the 
anaesthetic liquid in the vaporising chamber from 
entering the fresh gas line. There is no risk of agent 
spilling if the cassette is tilted as the inlet valve will 
close preventing any spillage. The vaporiser undergoes 
a daily self-check automatically when the anaesthesia 
workstation is switched on. Aladin cassette also has 
a pressure relief valve that works as a safety valve 
that opens whenever the pressure inside the Aladin 
cassette is greater than 2.5 bar.
Foong et al.[4] reported an accidental over-delivery of 
desflurane via Aisys Carestation Aladin 2 Cassette™ 
vaporiser. The inspired fraction of desflurane (FiDes) 
went up to 17.5% and 19.5% on two occasions during 
a procedure in end-tidal control delivery mode. Both 
episodes were managed by temporarily switching 
off desflurane and washing off desflurane with high 
FGF (6 l/min). The patient developed hypotension and 
tachycardia and required pharmacological intervention 
for restoration of haemodynamic parameters. Changing 
the cassette did not resolve the issues. However, similar 
situations could not be simulated later except on one 
occasion and it was classified as an intermittent error. 
Hence, vigilance is necessary while using automated 
drug delivery devices.
INJECTION VAPORISERS
Injection vaporisers[5,6] inject a known amount of liquid 
agent or pure vapour into the gas stream to provide desired 
concentration. The hallmark of injection vaporiser is that 
it enables rapid titration of anaesthetic depth with highly 
conservative low gas flows (metabolic flow) in a very 
short time (as short as 1 min), as a result, they minimise 
the wastage of the anaesthetic agents and prevent theatre 
pollution. Injection vaporisers were introduced with 
high-end anaesthesia workstations (Maquet FLOW-i and 
Drager Zeus).
It is worthwhile to know how the injection vaporiser 
can achieve the set targets of rapidly altering 
anaesthetic depth in 1 min with exceptionally low FGF. 
Rapid anaesthetic depth titration with low FGF can be 
achieved by first calculating the amount of sevoflurane 
vapour required to achieve 2% ETAC of sevoflurane 
in approximately 6000 mL capacity reservoir which is 
120 mL of vapour (120/6000 × 100 = 2%) where the 
reservoir comprises of patient’s functional residual 
capacity of 2000 mL and the anaesthesia circle breathing 
system capacity of 4000 mL. With a sevoflurane 
vaporiser set at 2%, the splitting ratio is 12:1. With FGF 
of 6000 mL/min, 5538 mL/min flows through the bypass 
chamber and 462 mL/min flows through the vaporising 
chamber and picks up 120 mL/min of sevoflurane 
vapour. The total vaporiser output is 6120 mL/min and 
sevoflurane will represent ~2% of that output.[7]
Hence, the percentage of sevoflurane vapour that 
a vaporiser should deliver to achieve 2% ETAC 
of sevoflurane in 1 min with 180 mL of FGF is 
equal to sevoflurane vapour/total FGF that is, 
120/(180 + 120) = 0.4 or 40% where 180 mL is the near 
metabolic FGF (3.5 mL/kg in a 50 kg person ~180 mL) 
and 120 mL is the sevoflurane vapour added to FGF. 
Thus, a vaporiser will have to deliver 40% sevoflurane 
in FGF of 180 mL to achieve the 2% ETAC of sevoflurane 
in 1 min. None of the vaporisers except the injection 
vaporisers can achieve this target in such a short time 
with near metabolic FGF.
Working principle: The anaesthetic agent is dispensed 
as liquid and that liquid has to be converted into the 
vapour state. Thus, the working principle involves 
the calculation of how much vapour will be generated 
by 1 mL of an anaesthetic agent. For example, the 
molecular weight of isoflurane is 184.5 and its specific 
gravity is 1.5 g/mL. Hence, applying Avogadro’s 
hypothesis 184.5 g/moles of isoflurane will occupy 
22.4 L at 273 K or 0and 760 mmHg. Therefore, 1 g/mole 
at 20 will occupy 22400/184.5 × 293/273 and 1 mL 
will give 22400/184.5 × 293/273 × 1.5 = 194 mL of 
isoflurane vapour.[8]
MAQUET INJECTION VAPORISER
The structural and functional components [Figure 5]: 
This is an electronically controlled injection type of 
Figure 4: Schematic illustration explaining the components and basic 
functional aspect of Aladin 1 cassette vaporiser. FGF = Fresh gas flow, 
Cassette ID = Cassette identification
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vaporiser that is used exclusively with the Maquet 
FLOW-i anaesthesia machine. The vaporisers weigh 
3.2 kg and are available for isoflurane, sevoflurane and 
desflurane.
The vaporiser consists of a liquid fill reservoir (container) 
with an agent capacity of 300 mL but at 260 mL it gives 
an indication of being 100% full. The electronic level 
indicator shows the anaesthetic liquid level with the 
help of a float in the illuminated metered tube. There 
are LEDs mounted at 6 different levels corresponding 
to 5, 10, 25, 50, 75 and 100%. The low and medium 
priority alarm is triggered at the level of 10 and 5%, 
respectively. However, the vaporiser does not switch 
off when it is empty. The vaporiser does not have a 
concentration control dial. The liquid container can 
be filled with an anaesthetic agent via filling port that 
has a safety fill valve to handle the pressure inside the 
liquid container. The safety valve is designed to handle 
different manufacturer’s specifications and filling 
systems (Isoflurane: Key fill, Sevoflurane: Key fill and 
Quick Fil™, Desflurane: Saf-T-Fil™). The vaporiser lid 
covers the safety valve and the filling port. Vaporiser 
lid position is monitored by a lid sensor and it must be 
closed to activate the vaporiser. The liquid container 
is also connected to a drive gas inlet to allow entry of 
a driving gas and pressurise the liquid in the reservoir. 
The liquid container is connected to the vaporising 
chamber via a vaporiser injector. The liquid container 
is provided by a gas escape pipe which helps to 
evacuate gas bubbles from the pressurised liquid 
anaesthetic before it reaches the vaporiser injector. The 
vaporiser pressure transducer measures the pressure 
of the liquid anaesthetic and a safety valve cuts off 
the supply of the pressurised liquid to the vaporiser 
injector device when the vaporiser or the system is 
off or on standby. The vaporiser injector delivers the 
pressurised liquid anaesthetic in the form of spray into 
the vaporising chamber. A nozzle plate is placed in 
front of the injector to convert the liquid into a spray. 
The injector’s opening is pulse controlled to achieve 
the set concentration of the anaesthetic. This pulsed 
liquid anaesthetic spray is monitored by the optical 
vaporiser injection device (OVID). The vaporising 
chamber is heated by the vaporising heating foil for 
uniform heating and converts the vapour spray into 
gas. The vaporising chamber has an inlet and an outlet 
for FGF. The FGF enters the vaporising chamber and 
gets mixed with the vaporised anaesthetic agent. The 
mixed FGF exits the vaporiser and is routed through 
the patient cassette.
Functional Anatomy: Drive gas from the anaesthesia 
workstation enters the liquid anaesthetic container 
from the top at 120 kPa and forces the pressurised liquid 
anaesthetic through a safety valve into the vaporiser 
injector. The vaporiser injector injects the liquid 
anaesthetic in a pulsed, intermittent manner into the 
heated vaporising chamber depending upon the set and 
the measured concentration. The spray is delivered in 
short pulses of 0.8 mL of agent per ms and the pulse 
time varies from 2–10 ms for isoflurane/sevoflurane 
and 5–10 ms for desflurane. Hence, the volume of agent 
injected per pulse is 1.6–8 mL for isoflurane/sevoflurane 
and 4–8 µL for desflurane. The OVID contains 2 PC 
boards i) vaporiser spray LED and ii) vaporiser spray 
detector which detects the presence of the spray 
of the anaesthetic agent into electronically heated 
vaporising chamber. The temperature of the vaporising 
chamber is monitored and maintained at 47°C for 
isoflurane/sevoflurane and 37°C for desflurane. 
Temperature of the vaporising chamber and heating 
foil is measured by separate temperature sensors. 1) 
The vaporising chamber temperature is monitored 
by 2 vaporising temperature sensors. The vaporiser 
gets switched off if the temperature of the vaporising 
chamber rises above 60°C or when the temperature 
difference of more than 5°C is detected between the 
2 sensors, 2) When the temperature of the heating foil 
goes beyond 140°C the heating foil is switched off, no 
alarms are activated and the heating is restarted once 
the temperature falls. But if the temperature exceeds 
170°C the vaporiser is switched off and a technical 
alarm is activated. The liquid rapidly evaporates in 
the vaporising chamber and this vapour is carried by 
the FGF coming in through the inlet valves. The mixed 
Figure 5: Schematic representation of components and function of 
Maquet injection vaporiser. VC temp. sensor = Vaporising chamber 
temperature sensor, Heating foil temp. sensor = Heating foil 
temperature sensor, S = sensor, R = Receiver
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The dosing chamber, whose pressure is monitored, is 
connected to the heated vaporising chamber through 
a dosing valve. This dosing valve is controlled by an 
electronic computer-controlled feedback control unit, 
which receives information about the FGF rate and 
set anaesthetic agent concentration (either fresh gas 
or ETAC). The feedback control unit thus controls the 
amount of liquid injected through the dosing valve 
into the heated vaporising chamber. The gas supply 
module [Figure 6c] is part of the anaesthesia machine. 
It consists of propellant gas (air) inlet, a non-return 
valve, a pressure buffer and pressure reducer and 
a supply valve through which gas (air) enters the 
metering module [Figure 6].[6]
Functional anatomy: When the vaporising module is 
placed in its slot it gets integrated with the gas supply 
module. The propellant gas (air) enters the metering 
module and propels the liquid anaesthetic through 
the liquid gate into the dosing chamber. The pressure 
in the dosing chamber is transmitted to the feedback 
control unit. Depending on the set agent concentration 
(that is transmitted electronically from the feedback 
control unit to the dosing valve) a fixed amount of 
liquid anaesthetic is injected into the heated vaporising 
chamber. The liquid anaesthetic is vaporised in the 
FGF exits the vaporising chamber through the outlet 
valves.[5]
DRAGER DIVA (DIRECT INJECTION OF VAPOUR 
ANAESTHETIC) VAPORISER
The Drager DIVA vaporiser which is integrated into the 
Zeus anaesthesia machine allows for target‑controlled 
anaesthesia with closed-loop quantitative control of 
the delivery of oxygen, carrier gas and anaesthetic 
vapour.
Structural and functional components: The Drager DIVA 
injection vaporiser can be categorised as measured 
flow vaporiser. The carrier gas and the anaesthetic 
agent is uncoupled and both are delivered separately 
into the system [Figure 6a]. The vaporiser integrated 
with the anaesthesia machine consists of 2 modules, 
a detachable vaporising or metering module that 
is anaesthetic specific and a fixed non-specific gas 
supply module that is inbuilt in the Zeus anaesthesia 
machine. The metering module [Figure 6b] stores 
the liquid anaesthetic in a reservoir with a coded 
filling system, liquid level indicator window and a 
ventilation outlet. It also houses a dosing chamber 
that is connected to the reservoir through a liquid gate. 
Figure 6: Gas flow schematic illustration of Zeus/Zeus IE rebreathing system. (a) Illustration showing uncoupled carrier gas and direct injection 
volatile agent (DIVA), both delivered separately into the circle system. (b) Schematic illustration showing the components and function of the 
metering module of DIVA vaporiser. (c) Schematic illustration of the gas module within the anaesthesia machine that gets integrated with the 
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heating chamber and passes through a flow sensor out 
of the metering module [Figure 6b].
The anaesthetic vapours can take one of the two 
pathways once they exit the metering module, 
depending on the mode set on the Zeus anaesthesia 
machine. If it is set at fresh gas control mode, the 
vapours pass through a fresh gas valve to a mixing 
chamber, where they mix with the FGF and the 
mixture is directed to the breathing system. If it is 
set in auto control mode, the vapours exit through 
another pathway, pass through the saturated vapour 
valve directly to the breathing system, where they mix 
with the FGF. Thus, in auto control mode, anaesthetic 
vapours and FGF are injected separately into the 
breathing system while in the fresh gas control 
mode; the system emulates a classical system with 
flowmeter and vaporiser. The electronic feedback 
control unit thus determines the amount of liquid 
that would be dosed through the dosing valve into 
the heated vaporisation chamber and controls the 
vapour output. Hence, quantitative closed-system 
anaesthesia or target-controlled anaesthesia can be 
achieved. The blower unit (TurboVent2) is the crucial 
component that creates the gas flow (inspiration) to 
the patient.
Salient features of injection vaporisers
Injection vaporisers are electronically and 
pneumatically operated with safety features that 
switch off the vaporiser with an audiovisual technical 
alarm when there is a malfunction of temperature and 
pressure. The vaporiser is not vulnerable to tipping as 
it has no wicks to saturate and agent cannot spill into 
the vaporising chamber. Filling of the vaporiser can be 
performed while the vaporiser is in use (though agent 
delivery does not happen during filling).
Struys et al.[9] compared time to reach desired ETAC, 
initial overshoot and stability at target ETAC and 
washout time using agents desflurane and sevoflurane 
between Zeus (Dräger, Lübeck, Germany) apparatus 
using direct injection of inhaled anaesthetics and 
Primus apparatus (Dräger, Lübeck, Germany) using a 
classic out-of-circle vaporiser. The authors observed 
that electronic control allows instantaneous changes 
in vapour concentrations to achieve set ETAC values 
even with very low FGF. In Zeus, the wash-out times 
were faster, inhaled anaesthetic concentration was 
the lowest, no overshoot at the target was seen and 
the time course of sevoflurane and desflurane was 
minimally influenced by changes in FGF.
AnaConDa VAPORISER
AnaConDa™ or Anaesthetic conserving device 
was the brainchild of Giebeck AB and introduced 
in the market by Sedana Medical, Stockholm, 
Sweden.[10] It is a miniature anaesthetic vaporiser and 
HME (humidified moisture exchanger) filter combined 
together. The device is meant to be used mainly for 
sedation in the intensive care unit (ICU) and outside 
operating rooms. It is designed to deliver only 
isoflurane and sevoflurane [Figure 7].
The structural and functional components: The 
AnaConDa™ the device has a colour-coded patient 
side (transparent) and a ventilator side (black) 
separated by a bilayer filter. It is a unique oval-shaped 
device where the ventilator inlet and the patient outlet 
are aligned parallel to the filter medium to facilitate 
laminar airflow. The device is customised to fit 
between the Y-piece and endotracheal tube (ETT) like 
an HME filter. The patient end has an outlet which 
can be connected directly to the ETT or a connector. 
The patient’s end has a gas sampling port connected 
with a standard Leur lock through which end-tidal 
gas monitoring can be performed. AnaConDa™ 
does not require any additional power supply for its 
operation [Figure 7]. The vaporiser should be placed at 
an angle of 45°. Internally in the vaporiser, the first layer 
of the bilayer filter is an electrostatic polypropylene 
filter, a protective layer situated towards the patient 
side, which prevents the ventilator from bacterial and 
viral contamination. The second layer is a thick 3–4 mm 
activated carbon felt adsorptive layer which adsorbs 
and reflects inhalational anaesthetics and moistures 
in the circuit. However, for proper functioning, the 
device should be replaced daily [Figure 8a].
AnaConDa™ is available presently in two different 
internal volumes of 100 and 50 mL to be used in 
Figure 7: Set up of AnaConDa™ vaporiser for use
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patients with high and low tidal volumes, respectively. 
AnaConDa™ (50 ml) is for the patients with less than 
50 kg body weight and a tidal volume of fewer than 
350 mL as a dead space of 100 mL will lead to inadequate 
carbon dioxide washout and thus may give rise to 
deleterious hypercapnia. The 50 mL device can be used 
even in patients with a tidal volume as low as 200 mL. 
While the 100 mL AnaConDa™ is recommended for 
tidal volumes ranging from 350–1200 mL. The 50 ml 
device is slightly less efficient (by approximately 2%) 
than the 100 mL device, therefore, requiring a slightly 
higher infusion rate for a desired end-tidal vapour 
concentration.
Functional anatomy: AnaConDa™ delivers constant 
inhalational agents to the patients despite having 
no measurement dials.[11] A porous polypropylene 
evaporator rod is mounted to the patient’s end of the 
device [Figure 8a]. The rod has an external agent line 
made of polyethylene connected to a 50 mL specially 
modified syringe mounted on a syringe pump. The 
agent line has an adaptor with a small spring valve 
which only opens when the syringe is fully fitted to 
the adaptor. This safety feature prevents anaesthetic 
agents from leaking backwards into the device at 
the time of syringe disconnection of the syringe for 
refilling. The device adaptor and the Syringe share 
unique thread different in diameter and look from 
other commonly used medical threads so that they are 
exclusively keyed to each other. Specially designed 
polyoxymethylene bottle adaptors are available for 
filling the syringe attached to the AnaConDa™. During 
inspiration [Figure 8b], the gas in the inspiratory limb 
picks up vapour from the evaporator rod and delivers 
it to the patient. During expiration [Figure 8c], the 
unabsorbed part of the anaesthetic vapour is absorbed 
by the thick carbon filter. A major portion (as high 
as 90%) of this absorbed vaporiser is delivered to 
the patient again (or ‘reflected’ back) in the next 
inspiration. The small amount of vapour which 
reaches the expiratory limb gets scavenged eventually. 
The rate of infusion of anaesthetic vapour depends on 
the type of vapour used (isoflurane and sevoflurane), 
patients’ mass and tidal volume used. Pharmacokinetic 
models for manually adjusted infusion rates have been 
tried with some success [Figure 8].[12]
The AnaConDa™ devices are validated by the 
manufacturers in bench-top tests as per ISO-9360 
standards for HME and HME filters.[13] The 
AnaConDa™ has a keyed system in the form of a 
unique thread that connects the adaptor and the 
syringe. Neither AnaConda™ can be connected to 
any other syringe than the customised one nor the 
syringe can be attached to any other Luer lock or other 
intravenous devices. AnaConDa™ by its recycling 
mechanism (activated carbon) saves anaesthetic 
vapours as well as prevents environmental pollution. 
Nishiyama et al. demonstrated that AnaConDa™ 
could save anaesthetic vapour consumption and 
fasten emergence from general anaesthesia versus 
conventional TEC vaporisers.[11] However, the device 
has certain limitations. AnaConDa™ creates a dead 
space effect larger than its internal volume due to 
reflection of carbon dioxide hence, it is used in patients 
with acute respiratory distress syndrome and other 
respiratory illness is questionable as it limits giving 
low tidal volume ventilation as well as increases the 
physiological dead space.[14]
Summary: The modern vaporisers have both electronic 
and pneumatic control and can deliver set or target 
anaesthetic agent concentration accurately. The FGF 
rates through the vaporisers may vary as in Aladin or 
constant as in Flow-I and DIVA to achieve the target 
agent concentration with minimal wastage and theatre 
pollution. They are designed to alleviate hazards 
and ensure safe, constant and effective delivery of 
inhalational anaesthetics to the patients.
Figure 8: Schematic cross‑section of AnaConDa™ vaporiser 
(a) Schematic cross‑section illustrating the inner components of 
AnaConDa™ vaporiser when switched off. (b) The flow of gases 
during inspiration through the AnaConDa™ vaporiser. (c) The flow of 
gases during the expiration phase through the AnaConDa™ vaporiser. 
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